// App-Quantinova.ai

: Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Researchers

Presenter

  • Raymond SM Wong

Principal Investigators

  • Humphrey W.H. Pullon

  • Pascal Deschatelets

  • Cedric G Francois

  • Mohamed Hamdani

  • Surapol Issaragrisil

  • Patrick Johnson

  • Pimjai Niparuck

  • Tontanai Numbenjapon

  • Jameela Sathar

  • Lisa Tan

  • Eric Tse

  • Federico Grossi

Medical Centers

  • Sir YK Pao Centre for Cancer & Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong

  • Waikato Hospital, Hamilton, NZL

  • Apellis Pharmaceuticals Inc, Crestwood, KY

  • Apellis Pharmaceuticals, Waltham, MA

  • Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand

  • JPharma Solutions GmbH, Zurich, Switzerland

  • Division of Hematology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand

  • Division of Hematology, Department of Internal Medicine, Phramongkutklao Hospital, Bangkok, Thailand

  • Department of Hematolgy, Ampang Hospital, Petlaing Jaya, MYS

  • Lisa Tan Pharma Consulting, Cambridge, United Kingdom

  • Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong

Locations

  • Hong Kong

  • United States

  • Switzerland

  • Thailand

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • APL-2

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved